Cosentyx vs Humira: How do they compare?

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 9, 2023.

Official Answer by Drugs.com

Both Cosentyx and Humira are available as subcutaneous injections (given under the skin) and may be used to treat certain inflammatory conditions such as plaque psoriasis, psoriatic arthritis, hidradenitis suppurativa, and ankylosing spondylitis. Cosentyx is also available as an IV injection that can be administered by a healthcare provider. After an initial loading dose, Humira is given every two weeks and Cosentyx every four weeks.

Both are biologics and are made from immune system cells, but reduce inflammation in different ways. Humira contains adalimumab and reduces inflammation by blocking the action of TNF-alfa (a signaling protein [also called a cytokine]) whereas Cosentyx contains secukinumab and works by stopping interleukin 17A from binding to the IL-17 receptor.

For people with psoriasis, Humira is only approved for adults but Cosentyx may be used in adults and children (age range varies depending on the condition being treated). No differences in effectiveness were found in a head-to-head trial comparing Cosentyx to Humira for psoriatic arthritis.

Key differences and similarities summarized include:

Humira contains adalimumab. Cosentyx contains secukinumab. Both are prescription medicines
Both are available in forms that are suitable for self-administration (such as a prefilled syringe, pen, or autoinjector), but Cosentyx is also available as an IV injection that can be administered by a healthcare provider for people who do not want to give themselves an injection.
Humira belongs to the class of medicines known as TNF-alfa (alpha) inhibitors. Cosentyx is an interleukin inhibitor
Humira is made by AbbVie Inc. and Cosentyx is made by Novartis Pharmaceuticals Corporation
Humira was FDA approved for psoriasis on the 18th Jan 2008 and Cosentyx was FDA approved for psoriasis on the 21st January 2015
Humira is approved in adults to treat moderate to severe chronic plaque psoriasis when other systemic therapies are medically less appropriate, rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, hidradenitis suppurativa, and uveitis. Cosentyx is approved to treat moderate to severe plaque psoriasis in adults and children over the age of two who require systemic therapy or phototherapy, active psoriatic arthritis in patients aged 2 years and older, adults with ankylosing spondylitis or non-radiographic axial spondyloarthritis with inflammation, adults with moderate to severe hidradenitis suppurativa, and active enthesitis-related arthritis in patients aged 4 years and over.
Humira is given SC (under the skin) injection at weeks 0 and 1, then every 2 weeks thereafter. Cosentyx is given SC at weeks 0, 1, 2, 3, and 4, then every 4 weeks thereafter
Common side effects of Humira include a headache, cold symptoms, rash, infections, or redness, bruising, or itching at the injection site. Common side effects of Cosentyx include infections (such as those affecting the lungs, nose, or skin), a stuffy or runny nose
Interactions, with medicines such as immunosuppressants, warfarin, and live vaccines are similar with either Cosentyx and Humira
Both are injections that need to be stored in the refrigerator at 2ºC to 8ºC (36ºF to 46ºF) before use
Both start working within a few weeks but it may take up to 4 months for the full effects of Cosentyx to be seen and up to 3 months for the full effects of Humira to develop
Cosentyx is associated with an increased risk of developing inflammatory bowel disease. Humira may help people with IBD and push the condition into remission. Humira is associated with an increased risk of certain cancers, such as skin cancer, lymphoma, and leukemia, heart problems, such as new or worsening heart failure, blood disorders, such as anemia, and other conditions
Very few studies have directly compared Cosentyx with Humira but one, called the EXCEED trial compared the two biologics in people with psoriatic arthritis. This trial showed that treatment with Cosentyx was similar to that with Humira (or that Cosentyx was not superior to Humira). However, people were more likely to stay on treatment than people assigned Humira. 67% of patients assigned Cosentyx achieved an ACR20 response at week 52 versus 62% of patients assigned (OR 1·30, 95% CI 0·98-1·72; p=0·0719). Seven (2%) of 426 patients in the Cosentyx group and six (1%) of 427 patients in the Humira group had serious infections.

How does Ilumya work to treat psoriasis?

Ilumya works by binding selectively to interleukin-23 (IL-23) which is a naturally occurring cytokine. IL-23 plays a key role in promoting inflammation and regulating other cytokines (such as IL-17) and inflammatory substances, such as TNF-α3-7. By blocking the effects of IL-23, Ilumya helps control the release of IL-17 and TNF-α, which reduces inflammation associated with psoriasis. It also decreases how many inflammatory cells are present within psoriatic lesions, helps prevent plaque formation, and resolves tissue damage. Continue reading

Prednisone: What are 12 Things You Should Know?

Prednisone first came onto the market over sixty years ago and is still going strong. But did you know that this common drug used for a variety of different conditions also has some pretty serious side effects as well? Continue reading

Where should you not use triamcinolone acetonide cream?

You should not use topical corticosteroids like triamcinolone acetonide cream on your face, groin, or axillae (underarm, armpit) unless directed by your doctor. Using triamcinolone in these areas may lead to unwanted side effects like acne, prominent blood vessels, skin thinning (atrophy), changes in skin color or unwanted hair growth. Continue reading

Cosentyx vs Humira: How do they compare?

Related questions

Read next

How does Ilumya work to treat psoriasis?

Prednisone: What are 12 Things You Should Know?

Where should you not use triamcinolone acetonide cream?

See also:

Aimovig

Botox

Otezla

Nurtec ODT

Emgality

Inderal

Ajovy

Vyepti

Botox Cosmetic

Fremanezumab

Related medical questions

Drug information

Related support groups